Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

IP 001

Next Previous
Drug Profile

IP 001

Alternative Names: GC - Immunophotonics; inCVAX-GC; inCVAX-IP001; inCVAX-N-dihydro-galacto-chitosan; IP-001

Latest Information Update: 29 Aug 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Immunophotonics
  • Developer Immunophotonics; Swiss Group for Clinical Cancer Research
  • Class Antineoplastics; Immunotherapies; Polysaccharides
  • Mechanism of Action Antigen presenting cell stimulants; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Colorectal cancer; Liver metastases; Malignant melanoma; Non-small cell lung cancer; Soft tissue sarcoma; Solid tumours
  • No development reported Breast cancer

Most Recent Events

  • 21 Aug 2025 Immunophotonics completes a phase I/II INJECTABL-1 trial for Solid tumours, Colon cancer, Non-small cell lung cancer, Soft tissue sarcoma (Second-line therapy or greater, Late-stage disease) in the USA, United kingdom, Switzerland and Germany (NCT06291935)
  • 21 Aug 2025 Immunophotonics completes a phase I/II trial for Solid tumours, Melanoma and Soft-tissue sarcoma (Second-line therapy or greater, Late-stage disease, Recurrent) in Switzerland (NCT03993678)
  • 07 Oct 2024 Phase-I/II clinical trials in Liver metastases (Second-line therapy or greater) in Netherlands (Intratumoural) (NCT06630624)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top